Abpro Holdings (ABPO) Receivables (2023 - 2026)
Abpro Holdings' (ABPO) quarterly Receivables came in at $1.1 million in Q1 2026, down 5.63% YoY from $1.1 million in Q1 2025, and up 2.0% on a QoQ basis from $1.1 million in Q4 2025.
Abpro Holdings (ABPO) Receivables (2023 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 4 years of Receivables data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Receivables fell 5.63% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 5.63% YoY) and the FY2025 annual result came in at $1.1 million, up 8.68% from the prior year.
- Receivables rose to $1.1 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $1.2 million in Q2 2025 to a low of $839000.0 in Q4 2023.
- A 4-year average of $1.1 million and a median of $1.1 million in 2026 frame the typical range for Receivables.
- Annual changes were most pronounced in 2024 — Receivables climbed 15.38% — and 2026, when it decreased 5.63%.
- Tracing ABPO's Receivables over 4 years: stood at $839000.0 in 2023, then rose by 15.38% to $968000.0 in 2024, then grew by 8.68% to $1.1 million in 2025, then increased by 2.0% to $1.1 million in 2026.
- The last three Receivables figures came in at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | 1.05 Mn |
| Sep 30, 2025 | 1.12 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 1.14 Mn |
| Dec 31, 2024 | 968,000.00 |
| Dec 31, 2023 | 839,000.00 |